How SeqOIA and AURAGEN genomic sequencing affects cancer care pathways
Official title: Indicateurs de Performance et Impact Sur le Parcours de Soins du Séquençage Sur Les Plateformes Seqoia et Auragen (Seqogen) Pour Les Patients en Oncologie
Run by Assistance Publique - Hôpitaux de Paris · NCT07147465 · Data updated 2026-11-12
This project tests whether genomic sequencing performed by the SeqOIA and AURAGEN platforms changes care and treatment recommendations for cancer patients referred for high‑throughput sequencing.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 3149 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 3 sites (Lyon and 2 other locations) |
| Status | Recruiting |
| Started | July 1, 2025 |
| Main results expected | July 31, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | August 29, 2025 |
| Trial ID | NCT07147465 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are cancer patients in France who were referred for high‑throughput genomic sequencing with upstream RCP validation since January 1, 2021 and who have consented to reuse of their medical and genomic data.
✕Probably not a fit
Patients who oppose reuse of their data, whose sequencing referral was not validated by the upstream RCP, or whose care is unlikely to be influenced by genomic findings may not receive benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
SONCO is an observational national cohort that collects clinical and molecular data from all cancer patients referred to the SeqOIA and AURAGEN sequencing platforms. It links molecular tumor board reports captured via digital tools (SPICE and HYGEN) with hospital medical records to track treatment recommendations and patient care trajectories before and after sequencing. The project captures operational and quality indicators such as turnaround time, quality of patient information, and measures of diagnostic and therapeutic impact. Results are intended to inform national guidelines and help plan the organization and resource needs for future genomic services across France.
Why it matters
Potential benefit: If successful, this work could help speed up and personalize treatment decisions and guide hospitals and policymakers in organizing genomic services.
How similar studies have gone: Previous genomic sequencing programs have shown clinical benefit for subsets of oncology patients, but combining platform performance and nationwide care‑pathway impact in a single cohort is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with cancer and referred for high-throughput sequencing * Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021. Consent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use. Exclusion Criteria: * Opposition to data reuse, unvalidated upstream RCP
Where it's running
-
Centre Leon Berard
Lyon, France Recruiting -
HOPITAL AP-HP Cochin
Paris, France Recruiting -
APHP Hôtel Dieu URC Economie de la sante /URC ECO
Paris, France Active not recruiting
Study contacts
- Principal investigator: Isabelle DURAND-ZALESKI, Professor — Greater Paris University Hospitals
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prospective blood collection to detect donor-derived cell-free DNA after kidney transplant
This project will collect blood from adults who had a kidney transplant to try a blood test that detects donor-derived cell-free DNA to check the transplanted organ.
-
Using advanced genetic testing to improve diagnosis of bile duct tumors
This study is testing a new genetic test to see if it can help doctors better diagnose bile duct tumors in patients who are having surgery.
-
Developing predictive risk models for pilots using advanced techniques
This study is trying to create personalized health risk models for high-performance pilots in the Italian Air Force to help keep them healthy and performing well in extreme conditions.
-
Registry of patients treated with heavy particle therapy for cancer
This study is collecting information from cancer patients treated with advanced heavy particle therapy to see how well it works and what side effects it might cause.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.